# Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

> **NCT04648930** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Xolair

## Key facts

- **NCT ID:** NCT04648930
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-27
- **Primary completion:** 2022-11-03
- **Final completion:** 2022-11-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04648930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04648930, "Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04648930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*